(Q95383063)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21912416%20AND%20SRC:MED&resulttype=core&format=json

24 May 2020

title

Chemotherapy: Is adjuvant chemotherapy an option for stage II colon cancer? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21912416%20AND%20SRC:MED&resulttype=core&format=json

24 May 2020

1 reference

Christophe Tournigand

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21912416%20AND%20SRC:MED&resulttype=core&format=json

24 May 2020

Aimery de Gramont

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21912416%20AND%20SRC:MED&resulttype=core&format=json

24 May 2020

publication date

13 September 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21912416%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Clinical Oncology

24 May 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21912416%20AND%20SRC:MED&resulttype=core&format=json

24 May 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21912416%20AND%20SRC:MED&resulttype=core&format=json

24 May 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21912416%20AND%20SRC:MED&resulttype=core&format=json

24 May 2020

page(s)

574-576

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21912416%20AND%20SRC:MED&resulttype=core&format=json

Randomised trials of HIV prevention

24 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.139

Revised TN categorization for colon cancer based on national survival outcomes data

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.139

Adjuvant chemotherapy for stage II colon cancer with poor prognostic features

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.139

Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.139

Current issues in adjuvant treatment of stage II colon cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.139

Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.139

Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.139

Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.139

Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.139

Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21912416

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCLINONC.2011.139

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21912416%20AND%20SRC:MED&resulttype=core&format=json

24 May 2020

1 reference